BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.21B

Market cap10.21B

Price-Earnings ratio

30.41

Price-Earnings ratio30.41

Dividend yield

—

Dividend yield—

Average volume

1.51M

Average volume1.51M

High today

$54.32

High today$54.32

Low today

$52.88

Low today$52.88

Open price

$53.87

Open price$53.87

Volume

262.59K

Volume262.59K

52 Week high

$66.28

52 Week high$66.28

52 Week low

$50.76

52 Week low$50.76

Stock Snapshot

The current BioMarin(BMRN) stock price is $53.08, with a market capitalization of 10.21B. The stock trades at a price-to-earnings (P/E) ratio of 30.41.

As of 2026-04-24, BioMarin(BMRN) stock has fluctuated between $52.88 and $54.32. The current price stands at $53.08, placing the stock +0.4% above today's low and -2.3% off the high.

The BioMarin(BMRN)'s current trading volume is 262.59K, compared to an average daily volume of 1.51M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $66.28 and a 52-week low of $50.76.

BMRN News

TipRanks 18h

BioMarin set to acquire Amicus after regulatory clearance

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 23h

BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial

Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...

Simply Wall St 2d

Is It Time To Reconsider BioMarin Pharmaceutical After Multi Year Share Price Weakness

Investors may be wondering whether BioMarin Pharmaceutical's share price lines up with its underlying value, especially after a mixed run for the stock. At a l...

Analyst ratings

81%

of 26 ratings

Buy

80.8%

Hold

19.2%

Sell

More BMRN News

Nasdaq 2d

BioMarin Appoints Ian Clark As Board Chair

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), on Tuesday, announced the appointment of Ian Clark as Chair of the Board, subject to his election at the compan...

TipRanks 3d

BioMarin appoints Ian Clark as Chair of the Board

BioMarin (BMRN) Pharmaceutical said that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company’s Annua...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.